The New England Journal of Medicine February 11, 1999

A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care

Paul C. Hébert, George Wells, Morris A. Blajchman, et al.

Bottom Line

The TRICC trial demonstrated that a restrictive red-cell transfusion strategy (hemoglobin < 7.0 g/dL) is as safe as, and potentially superior to, a liberal strategy (hemoglobin < 10.0 g/dL) in euvolemic, critically ill patients.

Key Findings

1. Overall 30-day mortality was similar between the restrictive and liberal transfusion groups (18.7% vs. 23.3%, P=0.11) [1.2.2].

2. Hospital mortality was significantly lower in the restrictive-strategy group compared to the liberal-strategy group (22.2% vs. 28.1%, P=0.05).

3. Among less severely ill patients (APACHE II score <= 20), 30-day mortality was significantly lower in the restrictive group (8.7% vs. 16.1%, P=0.03).

4. Among younger patients (age < 55 years), 30-day mortality was also significantly lower in the restrictive group (5.7% vs. 13.0%, P=0.02).

Study Design

Design

RCT

Open-Label

Sample

838

Patients

Duration

30 days

Median

Setting

Multicenter, Canada

Population Critically ill, euvolemic adults with a hemoglobin concentration < 9.0 g/dL within 72 hours after ICU admission.

Intervention Restrictive transfusion strategy (transfuse when hemoglobin < 7.0 g/dL, target 7.0 to 9.0 g/dL).

Comparator Liberal transfusion strategy (transfuse when hemoglobin < 10.0 g/dL, target 10.0 to 12.0 g/dL).

Outcome 30-day all-cause mortality.

Study Limitations

• The trial was terminated early with 838 patients enrolled out of a planned 1,620, leaving it potentially underpowered to detect a 5.5% absolute difference in the overall primary outcome [1.1.1].

• The open-label design could have introduced bias in concomitant patient management by treating physicians.

• Strict exclusion criteria (e.g., active blood loss, chronic anemia) limited the generalizability of the findings to these specific patient populations.

• It may not be applicable to patients with active acute coronary syndromes, as cardiovascular events trended differently and these patients were underrepresented.

Clinical Significance

TRICC fundamentally shifted transfusion practices worldwide by disproving the traditional '10/30' rule, establishing 7.0 g/dL as a safe and effective transfusion threshold for most critically ill patients, thereby reducing unnecessary blood transfusions and exposure to associated risks.

Historical Context

Historically, critical care physicians routinely transfused patients to maintain hemoglobin levels > 10 g/dL and hematocrit > 30% to maximize oxygen delivery. Prior to TRICC, this practice lacked rigorous randomized evidence and competed with growing concerns over transfusion-related harms. TRICC was the first major trial to effectively dismantle this dogma.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Based on the oxygen delivery equation (DO2), why might a hemoglobin of 7.0 g/dL be adequately tolerated by a resting, euvolemic ICU patient, and what are the physiological downsides of transfusing packed red blood cells to push hemoglobin to 10.0 g/dL?

Key Response

Tests understanding of DO2 = CO x (1.34 x Hb x SaO2 + 0.003 x PaO2). Emphasizes that pRBCs have altered rheology, such as the storage lesion and decreased 2,3-DPG, which impairs oxygen offloading, alongside risks like TRALI, TACO, and immunomodulation.

Resident

The TRICC trial established 7.0 g/dL as a safe transfusion threshold for many ICU patients, but what specific patient population in the ICU should prompt you to consider a higher threshold based on the study's subgroup analyses and subsequent literature?

Key Response

Residents must recognize that while 7 g/dL is standard, patients with active acute coronary syndromes or severe ischemic heart disease often warrant a higher threshold (e.g., 8 g/dL) because myocardial oxygen extraction is already maximal at rest and relies heavily on coronary blood flow.

Fellow

How does the concept of the 'storage lesion' and transfusion-related immunomodulation (TRIM) explain the paradoxically lower mortality seen in the less severely ill (APACHE II score 20 or less) and younger (under 55 years) subgroups assigned to the restrictive strategy in the TRICC trial?

Key Response

Younger and less severely ill patients have adequate physiologic reserve to tolerate anemia but are equally vulnerable to the inflammatory, rheological, and immunomodulatory harms of older banked blood. Thus, withholding unnecessary blood provides a net survival benefit.

Attending

The TRICC trial fundamentally shifted the ICU culture away from the '10/30 rule'. When teaching trainees who feel compelled to 'fix the number' in an asymptomatic anemic patient, how do you frame the intervention of a blood transfusion to shift their risk-benefit calculus?

Key Response

Attendings focus on heuristics and reframing. Framing pRBC transfusion as a 'liquid organ transplant' highlights the profound immunological and infectious risks, combating the normalization bias of wanting a normal lab value and reinforcing that less is often more.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The TRICC trial was designed with a primary outcome of 30-day all-cause mortality, where the difference between the restrictive and liberal groups yielded a p-value of 0.11. How does the difference between equivalence versus superiority testing impact the interpretation of this 'negative' primary outcome?

Key Response

The trial was powered to detect a 20 percent relative decrease in mortality, which it failed to do, making it formally a 'negative' superiority trial. However, the clinically accepted interpretation is non-inferiority, which formally requires a fundamentally different statistical design and prespecified margin.

Journal Editor

Given that the TRICC trial was an unblinded study where clinicians actively managed hemoglobin levels, what is the risk of performance bias, and how might the protocol violations (crossovers) have driven the results toward the null hypothesis?

Key Response

A critical reviewer would note the lack of blinding. If restrictive patients received 'liberal' transfusions or vice versa, the actual hemoglobin gaps narrow, making the groups more similar, diluting any true difference and artificially making the strategies appear equally safe.

Guideline Committee

Based on the TRICC trial and subsequent trials, how do current AABB and SCCM guidelines grade the recommendation for a restrictive transfusion strategy in stable ICU patients, and what specific clinical caveats prevent a universal recommendation?

Key Response

Current AABB guidelines strongly recommend a restrictive strategy (Hb < 7 g/dL) for hemodynamically stable ICU patients. Caveats preventing universal application include acute coronary syndromes, severe traumatic brain injury, and acute gastrointestinal bleeding, which require distinct evidence bases.

Clinical Landscape

Noteworthy Related Trials

2011

FOCUS Trial

n = 2,016 · NEJM

Tested

Restrictive transfusion threshold (Hb < 8 g/dL)

Population

Patients undergoing hip-fracture surgery with cardiovascular disease or risk factors

Comparator

Liberal transfusion threshold (Hb < 10 g/dL)

Endpoint

Death or inability to walk independently at 60 days

Key result: A restrictive transfusion strategy was non-inferior to a liberal strategy regarding rates of death and inability to walk independently, with no increase in in-hospital morbidity.

2014

TRISS Trial

n = 998 · NEJM

Tested

Restrictive transfusion threshold (Hb < 7 g/dL)

Population

Patients with septic shock

Comparator

Liberal transfusion threshold (Hb < 9 g/dL)

Endpoint

Death by 90 days

Key result: There was no significant difference in 90-day mortality or ischemic events between the restrictive and liberal transfusion strategy groups.

2017

TRICS III Trial

n = 5,243 · NEJM

Tested

Restrictive transfusion threshold (Hb < 7.5 g/dL)

Population

Moderate-to-high risk patients undergoing cardiac surgery

Comparator

Liberal transfusion threshold (Hb < 9.5 g/dL in ICU or operating room, < 8.5 g/dL on non-ICU ward)

Endpoint

Composite of death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis by day 28

Key result: A restrictive transfusion strategy was non-inferior to a liberal strategy with respect to severe perioperative adverse outcomes in major cardiac surgery.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis